GBA SELL-Celsius Holdings, Inc. (CELH)- OUT $92>>>> ($4 LOSS) I still like the chart but I have to respect the software call on the overall market now.
I am not in it yet sorry if that was confusing I mean are you with me with the whole idea of buying before this big reveal...
You know my opinion. I'll look when it's under $30. If you want to play with trucks, TA has my blessing. $54 I think there's a couple others too. Flying J, Pilot. I'll look.
This is a tough decision)))) up $10 - $20 in various accounts. Shares of MGM Resorts (NYSE:MGM) continue to perform well on the stock market since the depths of the pandemic, climbing 125% over the past year and 231% over the last 18 months. But the stock may have more room to run as operations continue to improve. Las Vegas has been on fire since the summer started, and online gambling is just starting to show its true potential. The one blemish is Macao, but that's not enough to overlook all of the positive trends behind MGM Resorts stock. Las Vegas is on fire You wouldn't know there is still a pandemic in the U.S. based on the gambling numbers in Las Vegas. In August, gambling win on the Las Vegas Strip was $625.7 million, and over the past three months, win was $2.02 billion, for an $8.08 billion annualized pace. For perspective on just how big those numbers are, the best year on record for the Las Vegas Strip was 2007 with $6.8 billion in gambling revenue. These gambling numbers are even before we see a real recovery in mid-week and convention revenue. In 2022 and beyond, when the convention business returns, we should see strong revenue, not only on the gambling floor but also from rooms, food and beverage, and other revenue sources. When looking at MGM Resorts stock, the Las Vegas Strip is the cash machine. It'll keep spitting out money and will allow the company to invest in growth opportunities, like online gambling. Online gambling is taking off MGM Resorts owns 50% of the BetMGM online gambling venture with Entain in the U.S., and that business is performing about as well as anyone could have hoped. In an update for investors, Entain said that BetMGM had a 23% market share in the U.S. for the three months ending in August and 26% share in the states where it operates. Better yet, it is battling for the No. 1 market position, which is a three-way battle with DraftKings (NASDAQKNG) and Flutter, which owns FanDuel. We will learn more about BetMGM's revenue and profits when MGM reports earnings, but for perspective on how the market sees online gambling, DraftKings has a market cap of $20.0 billion today, just shy of MGM's total market cap of $23.2 billion. If BetMGM has a larger share of the U.S. market than DraftKings, it bodes well for the value of MGM's 50% share of the venture
Which would you rather own? MGM at $48 or BYD at $66? I'll take Boyd. I've watched/played MGM for years. It spikes, and then flatlines forever. Boyd at least has $72 in it. Easy.
) VAN I SEE YOU IN OCULAR! YES! This may be the " big one " The one you sign off on. Thank You I'm Van and this has ben my day of clarity.-OCUL. The second small-cap stock we’ll look at is Ocular Therapeutix. As its name suggests, Ocular is a biopharma research firm working on new treatments for eye conditions. The company’s development focus is based on a proprietary technology, a bioresorbable hydrogel-based formulation. This gel is designed to deliver therapeutic agents directly to the eye without drops or injections. Ocular has two approved drugs on the market, Dextenza and ReSure. The first is indicated for post-surgical pain and inflammation of the eyes, and the second is an incision sealant to follow cataract surgery. Earlier this month, Ocular announced that Dextenza had received FDA approval of a Supplemental New Drug Application, for use treating itching symptomatic of allergic conjunctivitis. The company reported $11.1 million in sales of Dextenza for 2Q21, or 94% of the total $11.7 million in revenue. The remaining $600K in revenue was attributed to sales of ReSure. Sales of both drugs were up significantly from the year-ago quarter; Dextenza sales grew 692% year-over-year, while ReSure sales tripled. Ocular also maintains an active development pipeline, with its leading candidate, OTX-CSI, undergoing a Phase 2 clinical trial in the treatment of dry eye disease. The Phase 2 study has completed enrollment and top line data is expected during this fourth quarter period of 2021. Ahead of the upcoming top-line results from OTX-CSI, Raymond James' Dane Leone reiterated his Strong Buy rating on OCUL along with a $29 price target. Should his thesis play out, a potential upside of 159% could be in the cards. "The Phase 2 is expected to clarify the path forward towards registrational studies in dry eye. Based upon the potential dual mechanism of action (punctal plug pluscyclosporin), clinical differentiation will likely be based upon two primary factors 1) increase in tear production using the Schirmer score, and 2) tolerability versus drop formulation of cyclosporin (Restasis). We do not currently include OTX-CSI within our financial forecasts for OCUL, but given the fairly clear clinical hurdles required to run a successful dry eye disease drug development program, we think that the Phase 2 results for OTX-CSI could be an important value creating event for the pipeline," Leone opined.
TA jumped from 53.60 to $54.50 after my post Stoney. The algy's have found their savant. Be nice and I'll give the Slinger the blessing.
Well Boyd no Macau! So I like that. MGM has BETMGM I like that very much. Until MGM fully values or spins out BETMGM I have to favor them slightly. CZR is coming on strong. I'd have that order. 1.- MGM 2- Ceasars 3- Boyd 4- Red Rock